No Prescription |
 |
 | ||
|
Cosopt Generic Dorzolamide hydrochloride and Timolol |
|
| ||
No Prescription » Prescription Drugs 5 » Cosopt Generic Dorzolamide hydrochloride and Timolol Indications:COSOPT is indicated for the treatment of elevated intraocular pressure (IOP) in patients with:1.ocular hypertension 2.open-angle glaucoma 3.pseudoexfoliative glaucoma or other secondary open-angle glaucoma's and who are:insufficiently responsive to topical beta blocker monotherapy currently receiving concomitant antiglaucoma therapies such as dorzolamide HCI and timolol maleate.Dosage and Administration:The dose is one drop of COSOPT in the affected eye(s) two times daily. When substituting COSOPT for another ophthalmic antiglaucoma agent(s) discontinue the other agent(s) after proper dosing on one day and start COSOPT on the next day.If another topical ophthalmic agent is being used COSOPT and the other agent should be administered at least ten minutes apart.Safety and efficacy in paediatric patients below the age of 2 years have not been established. (For information regarding use in paediatric patients í¦2 years of age see Warnings and Precautions Paediatric Use). Buy Cosopt Generic Dorzolamide hydrochloride and Timolol and other Prescription Drugs 5 products online at Medstore. 5480
About Cosopt Generic Dorzolamide hydrochloride and Timolol: Product Type: Prescription Drugs 5 Cosopt ( Generic Dorzolamide hydrochloride and Timolol ) Cosopt (Generic Dorzolamide hydrochloride and Timolol) Generic Dorzolamide hydrochloride and Timolol 20mg/5mg 5mL Generic Dorzolamide hydrochloride and Timolol Cosopt
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
